Influence of excipients in antiglaukoma eye drops on quality of life index based on criteria of side effects frequency
Following the growth of overall morbidity, environmental degradation, social and economic vulnerability of the population, the demand for the effective and cheap medicines, which can provide an individual approach to the patient, is increasing. This can be achieved by taking into account not only peculiarities of the pharmacological action of medicines, but also the nomenclature of excipients.
The aim of this article was to study the nomenclature, technological properties, side effects and the influence of excipients on the quality of patients’ life.
There were analyzed 247 questionnaires assessing the quality of patients’ life with primary open-angle glaucoma to determine the frequency of side effects from the drug therapy. In order to determine the range and purpose of excipients, the marketing and merchandising analysis of eye drops S01E group – «Antiglaucoma agents and miotiks» available at the domestic pharmaceutical market were conducted.
Marketing analysis of the Ukrainian pharmaceutical market had shown the presence of 48 antiglaucoma medicines in the form of eye drops, which contain sympathomimetics, parasympathomimetics, carbonic anhydrase inhibitors, beta-adrenergic blockers, prostaglandin analogs.
The adjuvants for group S01E – «Antiglaucoma agents and miotiks» are solvents (100%), stabilizers (22.92%), isotonizing agents (39.58%), prolongators (52.08%), preservatives (100 %), buffers (72.92%), substances - pH regulators (39.58%), solubilizers (44.17%).
The most common preservative in antiglaucoma eyedrops is benzalkonium chloride. The chemical stability of the active ingredients is provided mainly by the addition of disodium edetate.
As a result of the analysis of forms «Quality of life in patients with primary open angle glaucoma» it has been set, that the correlation coefficient between the contents of auxiliary substances and frequency of side effects of antiglaucoma eyedrops ranges from 0.5 to 0.7, indicating a significant excipients impact on quality of patients’ life.
2. Peppers I. M. et al. Auxiliary substances in medicine technology: influence on technological, consumer, economic characteristics and therapeutic effectiveness: Teaching. manual for studio higher pharmacy tutor shut up / Ed. I. M. Perceva. - Kharkiv: Golden Pages, 2010. - 600 p.
3. Compendium on-line [Electronic resource]. - Mode of access: http://compendium.com.ua
4. Krivyaz O. V. Assessment of quality of life of patients with primary open-angle glaucoma // Mat. VІІ sciences-practice. Internet-conference "Pharmacoeconomics in Ukraine: the state and prospects of development". - Kharkiv: View of the NFUU, 2014. - pp. 42-44.
5. Baudouin C. The harmful effect of preservatives in eyedrops: implications for the treatment of glaucoma // Acta Ophthalmol. - 2008. - V. 86, N 7. - P. 716-726.
6. Epstein S. P. et al. Comparative toxicity of preservatives in immortalized corneal and conjunctival epithelial cells // J. Ocul. Pharmacol Ther - 2009. - V. 25, N 2. - P. 113-119.
7. Asada H. et al. Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy // Yakugaku. Zasshi - 2010. - V. 130, N 6. - P. 867-871.
This work is licensed under a Creative Commons Attribution 4.0 International License.